Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company at the forefront of developing cell and exosome-based therapies, has shared encouraging three-year safety and efficacy results from its ongoing HOPE-2 open label extension (OLE) study. The study investigates the effects of deramiocel (CAP-1002), Capricor’s leading therapeutic candidate, on Duchenne muscular dystrophy (DMD), particularly focusing on cardiac aspects […]
Pfizer Inc. (NYSE: PFE), a global leader in pharmaceuticals, faced a setback as their CIFFREO Phase 3 study did not meet its primary endpoint. The study aimed to evaluate the effectiveness of the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in improving motor function among ambulatory boys with Duchenne muscular dystrophy (DMD) aged 4 to 7 […]
Pfizer, the US pharmaceutical giant, has announced the discontinuation of two ongoing clinical trials for its drug domagrozumab (PF-06252616), intended to treat Duchenne muscular dystrophy (DMD). This decision comes after the trials failed to meet primary efficacy endpoints. The trials, identified as B5161002 and B5161004, were designed to evaluate the safety and efficacy of domagrozumab, […]
US based Exonics Therapeutics has secured $5 million seed funding from CureDuchenne Ventures, a subsidiary of nonprofit DMD advocacy group, CureDuchenne to advance its therapy for Duchenne Muscular Dystrophy, a severe form of muscular dystrophy.
Exonics Therapeutics, a biotechnology firm based in Boston, Massachusetts, has secured $5 million in seed funding from CureDuchenne Ventures, a subsidiary of the nonprofit Duchenne Muscular Dystrophy (DMD) advocacy group, CureDuchenne. This funding is aimed at further developing gene editing technologies, including CRISPR/Cas9, to potentially offer a curative therapy for Duchenne Muscular Dystrophy, a severe […]
